Eaton Vance Management Bluebird Bio, Inc. Transaction History

Eaton Vance Management

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$4.07 - $10.6 $2,035 - $5,300	-500 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$8.96 - $16.31 $80 - $146	-9 Reduced 1.77%	500 $5,000
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $793 - $971	-44 Reduced 7.96%	509 $16,000
Q1 2021 May 17, 2021	BUY	$16.59 - $33.89 $9,174 - $18,741	553 New	553 $17,000
Q1 2020 May 14, 2020	SELL	$26.16 - $63.5 $2.04 Million - $4.95 Million	-77,885 Closed	0 $0
Q4 2019 Feb 11, 2020	SELL	$46.96 - $61.67 $7.44 Million - $9.77 Million	-158,406 Reduced 67.04%	77,885 $6.83 Million
Q3 2019 Nov 14, 2019	SELL	$59.47 - $93.1 $1.14 Million - $1.78 Million	-19,157 Reduced 7.5%	236,291 $21.7 Million
Q2 2019 Nov 21, 2019	BUY	$75.84 - $105.21 $8,342 - $11,573	110 Added 0.04%	255,448 $32.5 Million
Q2 2019 Aug 16, 2019	BUY	$75.84 - $105.21 $16 Million - $22.3 Million	211,569 Added 483.38%	255,338 $32.5 Million
Q1 2019 May 14, 2019	BUY	$64.44 - $104.11 $1.37 Million - $2.21 Million	21,237 Added 94.25%	43,769 $6.89 Million
Q4 2018 Feb 07, 2019	BUY	$59.1 - $93.26 $478,887 - $755,685	8,103 Added 56.16%	22,532 $2.24 Million
Q2 2018 Aug 10, 2018	BUY	$99.64 - $127.59 $1.44 Million - $1.84 Million	14,429 New	14,429 $2.27 Million

128

62.8M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $542M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

Stay updated on Eaton Vance Management with notifications on news.